In Vivo Dosimetry With a Linear MOSFET Array to Evaluate the Urethra Dose During Permanent Implant Brachytherapy Using Iodine-125

Gurp, Esther J. Bloemen-van; Haanstra, Bjoerk K.C.; Murrer, L.; Gils, F. C. J. M. Van; Dekker, André; Mijnheer, Ben J.; Lambin, Philippe

doi:10.1016/j.ijrobp.2009.04.042

Cited by 16 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Haughey et al [11] used a metal-oxide semiconductor field effect transistor (MOSFET) linear array inside the rectum during HDR prostate brachytherapy but concluded that the approach was not suitable due to the difficulties of quantifying uncertainties in MOSFET response. IVD in permanent seed implant prostate brachytherapy has also been investigated [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

Material and methods IVD was performed for 40 treatments planned using intra-operative trans-rectal ultrasound (TRUS) with a MOSFET inserted into an additional needle. Post-treatment TRUS images were acquired for 20 patients to assess needle movement. Monte Carlo simulations of treatment plans were performed for 10 patients to assess impact of heterogeneities.Per-needle and total plan uncertainties were estimated and retrospectively applied to the measured data as error detection thresholds. ResultsThe mean measured dose was -6.4% compared to prediction (range +5.1% to -15.2%). Needle movement and heterogeneities accounted for -1.8% and -1.6% of this difference respectively (mean values for the patients analysed). Total plan uncertainty (k=2) ranged from 11% to 17% and per needle uncertainty (k=2) ranged from 18% to 110% (mean 31%). One out of 40 plans and 5% of needles were outside k=2 error detection threshold. Conclusions

show abstract

Section: Introductionmentioning

confidence: 99%

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Mason¹,

Mamo²,

Al-Qaisieh³

et al. 2016

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…However MOSFETs have problems including anisotropic response, energy dependence, variation in uncertainty with dose rate and total dose, and variation in response with accumulated dose. 11 As there are few published studies on the use of MOSFETs for low energy brachytherapy dosimetry [12][13][14] and in order to gain experience for possible future in vivo work, it was decided to use MOSFETs for the benchmarking work described in this study.…”

Section: Introductionmentioning

confidence: 99%

Monte Carlo investigation of I‐125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Bloemen-van Gurp et al 34,80 performed two studies in 2009 using a linear MOSFET array during permanent prostate implant. The overall uncertainty in the measurement procedure, determined in a simulation experiment, was 8.0% and an action level of ±16% (2 SD) for detection of errors in the implantation procedure is achievable after validation of the detector system and measurement conditions.…”

Section: Vc Mosfet Detectorsmentioning

confidence: 99%

In vivo dosimetry in brachytherapy

et al. 2013

View full text Add to dashboard Cite

In vivo dosimetry (IVD) has been used in brachytherapy (BT) for decades with a number of different detectors and measurement technologies. However, IVD in BT has been subject to certain difficulties and complexities, in particular due to challenges of the high-gradient BT dose distribution and the large range of dose and dose rate. Due to these challenges, the sensitivity and specificity toward error detection has been limited, and IVD has mainly been restricted to detection of gross errors. Given these factors, routine use of IVD is currently limited in many departments. Although the impact of potential errors may be detrimental since treatments are typically administered in large fractions and with high-gradient-dose-distributions, BT is usually delivered without independent verification of the treatment delivery. This Vision 20/20 paper encourages improvements within BT safety by developments of IVD into an effective method of independent treatment verification.

show abstract

In Vivo Dosimetry With a Linear MOSFET Array to Evaluate the Urethra Dose During Permanent Implant Brachytherapy Using Iodine-125

Cited by 16 publications

References 12 publications

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Real-time in vivo dosimetry in high dose rate prostate brachytherapy

Monte Carlo investigation of I‐125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET

In vivo dosimetry in brachytherapy

Contact Info

Product

Resources

About